In contrast, patients who received apaziquone between 30 and 90 min after TURBT demonstrated a highly significant response to apaziquone in terms of 2-year recurrence rates.
← all excerpts
Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer.
2
—
—
The sentences
The results of two phase III clinical trials were, however, disappointing, and when analysed individually, both studies failed to reach statistical significance for the primary end point which was the 2 year recurrence rate [ 10 ].